Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million
Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time
Senseonics Announces Commencement of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
Senseonics Announces European Launch of Eversense® 365, The World's First and Only One Year CGM System
First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear
Senseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose Monitor
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
